Marc Cobo
CIK: 0001816654
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
BridgeBio Oncology Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Oct 21, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
Tax Payment(F)Direct203 shares at avg. $2.68$544.04 - Oct 1, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
Tax Payment(F)Direct126 shares at avg. $3.94$496.44 - Sep 10, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
Award(A)Direct9K shares- - Sep 10, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
Tax Payment(F)Direct203 shares at avg. $5.52$1K - Jul 1, 2026BBOT
BridgeBio Oncology Therapeutics, Inc.
Tax Payment(F)Direct125 shares at avg. $7.80$975
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 21, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Tax Payment(F) | 203 | $2.68 | $544 | Direct |
| Oct 1, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Tax Payment(F) | 126 | $3.94 | $496 | Direct |
| Sep 10, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Award(A) | 9,038 | - | $0 | Direct |
| Sep 10, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Tax Payment(F) | 203 | $5.52 | $1,121 | Direct |
| Jul 1, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | Tax Payment(F) | 125 | $7.80 | $975 | Direct |
1-5 of 5 transactions
About Cobo Marc
Cobo Marc (SEC CIK 0001816654) files insider reports with the SEC as Principal Accounting Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT).
Signal8 holds 4 ownership filings by Cobo Marc, all Form 4s, filed between Jul 6, 2026 and Oct 23, 2026. Those filings report 5 transactions, from Jul 1, 2026 to Oct 21, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cobo Marc's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Cobo Marc
- Oct 21, 2026: Tax withholding of BBOT shares (Form 4, code F).
- Oct 1, 2026: Tax withholding of BBOT shares (Form 4, code F).
- Sep 10, 2026: Grant or award of BBOT shares (Form 4, code A).
- Sep 10, 2026: Tax withholding of BBOT shares (Form 4, code F).
- Jul 1, 2026: Tax withholding of BBOT shares (Form 4, code F).
Other insiders filing for BridgeBio Oncology Therapeutics, Inc. (BBOT)
- Elmelech Idan, COO & Principal Financial Ofcr
- Beltran Pedro, President and CEO
- Ben Yong, Chief Med & Dev Officer
- Chen Bihua, Director
- Tipirneni Praveen P., Director
- MCCORMICK FRANK, Director